Truist Securities maintains Gilead Sciences at Buy, raises price target to $181 from $158

What happened

Truist Securities kept its Buy rating on Gilead Sciences and raised its price target to $181 from $158, a 14.6% increase. That new target implies 9.3% upside from the October 29 close of $165.61.

Confirmed

Global impact / market context

A higher price target signals that this analyst expects more room for the stock to rise, which can draw attention from investors who follow analyst ratings. It may support demand for shares, but the target is an opinion, not a promise of future returns.

Analyst inference

Recent analyst targets for Gilead range from $131 to $200 across five notes in the past 30 days, showing divided views on how much the stock can gain. That wide spread means the new $181 target sits in the middle of current expectations, not at the top.

Analyst inference

What to watch

1. Watch whether other analysts change their Gilead ratings or price targets after Truist's move, since the recent range of targets runs from $131 to $200. Confirmed
2. Track whether Gilead shares move toward the $181 target or stay near the $165.61 close, which would show how much investors accept the analyst's view. Analyst inference
3. Consider comparing the target with the company's future earnings and drug sales updates, because analyst targets often change when new financial results or product news arrive. Proposed

Evidence

• Original source link unavailable